Sub-chronic agmatine treatment modulates hippocampal neuroplasticity and cell survival signaling pathways in mice

Journal of Psychiatric Research

Volumn 58, Issue , 2014, Pages 137-146

  Freitas, Andiara E ^a   Bettio, Luis E B ^a   Neis, Vivian B ^a   Moretti, Morgana ^a   Ribeiro, Camille M ^a   Lopes, Mark W ^a   Leal, Rodrigo B ^a   Rodrigues, Ana Lúcia S ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Agmatine; Akt; BDNF; CREB; ERK1 2; GSK 3 ; JNK1 2; PKA

Indexed keywords

AGMATINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PROTEIN KINASE C; STRESS ACTIVATED PROTEIN KINASE 1; ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; HIPPOCAMPUS; IMMOBILITY; LOCOMOTION; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; OPEN FIELD TEST; SIGNAL TRANSDUCTION; TAIL SUSPENSION TEST; WESTERN BLOTTING; ANALYSIS OF VARIANCE; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; IMMOBILIZATION; METABOLISM; TONIC IMMOBILITY;

AGMATINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; CELL SURVIVAL; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FEMALE; GENE EXPRESSION REGULATION; HINDLIMB SUSPENSION; HIPPOCAMPUS; IMMOBILITY RESPONSE, TONIC; MICE; NEURONAL PLASTICITY; SIGNAL TRANSDUCTION;

EID: 84912078381     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.07.024     Document Type: Article

References (93)

1. Abdel-Wahab B.A., Salama R.H. Venlafaxine protects against stress-induced oxidative DNA damage in hippocampus during antidepressant testing in mice. Pharmacol Biochem Behav 2011, 100:59-65.
2. Beaulieu J.M., Gainetdinov R.R., Caron M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 2009, 49:327-347.
3. Bubici C., Papa S., Pham C.G., Zazzeroni F., Franzoso G. The NF-kappaB-mediated control of ROS and JNK signaling. Histol Histopathol 2006, 21:69-80.
4. Borsello T., Forloni G. JNK signalling: a possible target to prevent neurodegeneration. Curr Pharm Des 2007, 13:1875-1886.
5. Bullock B.P., Habener J.F. Phosphorylation of the cAMP response element binding protein CREB by cAMP-dependent protein kinase A and glycogen synthase kinase-3 alters DNA-binding affinity, conformation, and increases net charge. Biochemistry 1998, 37:3795-3809.
6. Castrén E., Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol 2010, 70:289-297.
7. Chuang D.M. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?. Crit Rev Neurobiol 2004, 16:83-90.
8. Cordova F.M., Rodrigues A.L., Giacomelli M.B., Oliveira C.S., Posser T., Dunkley P.R., et al. Lead stimulates ERK1/2 and p38MAPK phosphorylation in the hippocampus of immature rats. Brain Res 2004, 998:65-72.
9. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
10. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005, 29:571-625.
11. Duric V., Banasr M., Licznerski P., Schmidt H.D., Stockmeier C.A., Simen A.A., et al. Anegative regulator of MAP kinase causes depressive behavior. Nat Med 2010, 16:1328-1332.
12. Dwivedi Y., Rao J.S., Rizavi H.S., Kotowski J., Conley R.R., Roberts R.C., et al. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003, 60:273-282.
13. Dwivedi Y., Rizavi H.S., Conley R.R., Pandey G.N. ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf. Mol Psychiatry 2006, 11:86-98.
14. Dwivedi Y., Rizavi H.S., Roberts R.C., Conley R.C., Tamminga C.A., Pandey G.N. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. JNeurochem 2001, 77:916-928.
15. Dwivedi Y., Rizavi H.S., Shukla P.K., Lyons J., Faludi G., Palkovits M., et al. Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits. Biol Psychiatry 2004, 55:234-243.
16. Dwivedi Y., Rizavi H.S., Zhang H., Roberts R.C., Conley R.R., Pandey G.N. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1). Int J Neuropsychopharmacol 2009, 12:1337-1354.
17. Elhwuegi A.S. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:435-451.
18. First M., Gil-Ad I., Taler M., Tarasenko I., Novak N., Weizman A. The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression. JMol Neurosci 2011, 45:246-255.
19. Fišar Z., Hroudová J. Intracellular signalling pathways and mood disorders. Folia Biol (Praha) 2010, 56:135-148.
20. Freitas A.E., Budni J., Lobato K.R., Binfaré R.W., Machado D.G., Jacinto J., et al. Antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice: evidence for the involvement of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:335-343.
21. Freitas A.E., Bettio L.E., Neis V.B., Santos D.B., Ribeiro C.M., Rosa P.B., et al. Agmatine abolishes restraint stress-induced depressive-like behavior and hippocampal antioxidant imbalance in mice. Prog Neuropsychopharmacol Biol Psychiatry 2013, 50:143-150.
22. Freitas A.E., Machado D.G., Budni J., Neis V.B., Balen G.O., Lopes M.W., et al. Antidepressant-like action of the bark ethanolic extract from Tabebuia avellanedae in the olfactory bulbectomized mice. JEthnopharmacol 2013, 145:737-745.
23. Freitas A.E., Moretti M., Budni J., Balen G.O., Fernandes S.C., Veronezi P.O., et al. NMDA receptors and the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway are implicated in the antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice. JMed Food 2013, 16:1030-1038.
24. Freitas A.E., Machado D.G., Budni J., Neis V.B., Balen G.O., Lopes M.W., et al. Fluoxetine modulates hippocampal cell signaling pathways implicated in neuroplasticity in olfactory bulbectomized mice. Behav Brain Res 2013, 237:176-184.
25. Freyberg Z., Ferrando S.J., Javitch J.A. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 2010, 167:388-396.
26. Gass P., Riva M.A. CREB, neurogenesis and depression. Bioessays 2007, 29:957-961.
27. Gourion D. Antidepressants and their onset of action: a major clinical, methodological and pronostical issue. Encephale 2008, 34:73-81.
28. Gourley S.L., Wu F.J., Kiraly D.D., Ploski J.E., Kedves A.T., Duman R.S., et al. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol Psychiatry 2008, 63:353-359.
29. Grimes C.A., Jope R.S. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. JNeurochem 2001, 78:1219-1232.
30. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001, 65:391-426.
31. Gumuslu E., Mutlu O., Sunnetci D., Ulak G., Celikyurt I.K., Cine N., et al. The effects of tianeptine, olanzapine and fluoxetine on the cognitive behaviors of unpredictable chronic mild stress-exposed mice. Drug Res (Stuttg) 2013, 63:532-539.
32. Harper S.J., LoGrasso P. Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38MAPK. Cell Signal 2001, 13:299-310.
33. Heninger G.R., Delgado P.L., Charney D.S. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996, 29:2-11.
34. Hodes G.E., Hill-Smith T.E., Lucki I. Fluoxetine treatment induces dose dependent alterations in depression associated behavior and neural plasticity in female mice. Neurosci Lett 2010, 484:12-16.
35. Hu J., Luo C.X., Chu W.H., Shan Y.A., Qian Z.M., Zhu G., et al. 20-Hydroxyecdysone protects against oxidative stress-induced neuronal injury by scavenging free radicals and modulating NF-κB and JNK pathways. PLoS One 2012, 7:e50764.
36. Hwang J., Zheng L.T., Ock J., Lee M.G., Kim S.H., Lee H.W., et al. Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology 2008, 55:826-834.
37. Jacobs K.M., Bhave S.R., Ferraro D.J., Jaboin J.J., Hallahan D.E., Thotala D. GSK-3β: a bifunctional role in cell death pathways. Int J Cell Biol 2012, 2012:930710.
38. Johannessen M., Moens U. Multisite phosphorylation of the cAMP response element-binding protein (CREB) by a diversity of protein kinases. Front Biosci 2007, 12:1814-1832.
39. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38MAPK protein kinases. Science 2002, 298:1911-1912.
40. Larsen M.H., Mikkelsen J.D., Hay-Schmidt A., Sandi C. Regulation of brain-derived neurotrophic factor (BDNF) in the chronic unpredictable stress rat model and the effects of chronic antidepressant treatment. JPsychiatr Res 2010, 44:808-816.
41. Lee R., Kermani P., Teng K.K., Hempstead B.L. Regulation of cell survival by secreted proneurotrophins. Science 2001, 294:1945-1948.
42. Lonze B.E., Ginty D.D. Function and regulation of CREB family transcription factors in the nervous system. Neuron 2002, 35:605-623.
43. Lopes M.W., Soares F.M., de Mello N., Nunes J.C., de Cordova F.M., Walz R., et al. Time-dependent modulation of mitogen activated protein kinases and AKT in rat hippocampus and cortex in the pilocarpine model of epilepsy. Neurochem Res 2012, 37:1868-1878.
44. Lopes M.W., Soares F.M., de Mello N., Nunes J.C., Cajado A.G., de Brito D., et al. Time-dependent modulation of AMPA receptor phosphorylation and mRNA expression of NMDA receptors and glial glutamate transporters in the rat hippocampus and cerebral cortex in a pilocarpine model of epilepsy. Exp Brain Res 2013, 226:153-163.
45. Maes M., Fišar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20:127-150.
46. Masi G., Brovedani P. The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression. CNS Drugs 2011, 25:913-931.
47. Matsuzawa A., Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta 2008, 1780:1325-1336.
48. Molteni R., Calabrese F., Racagni G., Fumagalli F., Riva M.A. Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol Ther 2009, 124:74-85.
49. Moretti M., Colla A., de Oliveira Balen G., dos Santos D.B., Budni J., de Freitas A.E., et al. Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress. JPsychiatr Res 2012, 46:331-340.
50. Munshi A., Ramesh R. Mitogen-activated protein kinases and their role in radiation response. Genes Cancer 2013, 4:401-408.
51. Nair A., Vaidya V.A. Cyclic AMP response element binding protein and brain-derived neurotrophic factor: molecules that modulate our mood?. JBiosci 2006, 31:423-434.
52. Neis V.B., Manosso L.M., Moretti M., Freitas A.E., Daufenbach J., Rodrigues A.L. Depressive-like behavior induced by tumor necrosis factor-α is abolished by agmatine administration. Behav Brain Res 2014, 261:336-344.
53. Neto F.L., Borges G., Torres-Sanchez S., Mico J.A., Berrocoso E. Neurotrophins role in depression neurobiology: a review of basic and clinical evidence. Curr Neuropharmacol 2011, 9:530-552.
54. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. JNeurosci 1995, 15:7539-7547.
55. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. JNeurosci 1996, 16:2365-2372.
56. Nijboer C.H., Bonestroo H.J., Zijlstra J., Kavelaars A., Heijnen C.J. Mitochondrial JNK phosphorylation as a novel therapeutic target to inhibit neuroinflammation and apoptosis after neonatal ischemic brain damage. Neurobiol Dis 2013, 54:432-444.
57. Numakawa T., Suzuki S., Kumamaru E., Adachi N., Richards M., Kunugi H. BDNF function and intracellular signaling in neurons. Histol Histopathol 2010, 25:237-258.
58. Ord E.N., Shirley R., McClure J.D., McCabe C., Kremer E.J., Macrae I.M., et al. Combined antiapoptotic and antioxidant approach to acute neuroprotection for stroke in hypertensive rats. JCereb Blood Flow Metab 2013, 33:1215-1224.
59. Pandey G.N., Dwivedi Y., Ren X., Rizavi H.S., Mondal A.C., Shukla P.K., et al. Brain region specific alterations in the protein and mRNA levels of protein kinase A subunits in the post-mortem brain of teenage suicide victims. Neuropsychopharmacology 2005, 30:1548-1556.
60. Papa S., Bubici C., Zazzeroni F., Pham C.G., Kuntzen C., Knabb J.R., et al. The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ 2006, 13:712-729.
61. Papa S., Zazzeroni F., Pham C.G., Bubici C., Franzoso G. Linking JNK signaling to NF-kappaB: a key to survival. JCell Sci 2004, 117:5197-5208.
62. Perez J., Tardito D., Racagni G., Smeraldi E., Zanardi R. cAMP signaling pathway in depressed patients with psychotic features. Mol Psychiatry 2002, 7:208-212.
63. Peterson G.L. Asimplification of the protein assay method of Lowry etal. which is more generally applicable. Anal Biochem 1977, 83:346-356.
64. Pilar-Cuéllar F., Vidal R., Díaz A., Castro E., dos Anjos S., Pascual-Brazo J., et al. Neural plasticity and proliferation in the generation of antidepressant effects: hippocampal implication. Neural Plast 2013, 2013:537265.
65. Piletz J.E., Aricioglu F., Cheng J.T., Fairbanks C.A., Gilad V.H., Haenisch B., et al. Agmatine: clinical applications after 100 years in translation. Drug Discov Today 2013, 18:880-893.
66. Posser T., de Aguiar C.B., Garcez R.C., Rossi F.M., Oliveira C.S., Trentin A.G., et al. Exposure of C6 glioma cells to Pb(II) increases the phosphorylation of p38 (MAPK) and JNK1/2 but not of ERK1/2. Arch Toxicol 2007, 81:407-414.
67. Qi X., Lin W., Li J., Pan Y., Wang W. The depressive-like behaviors are correlated with decreased phosphorylation of mitogen-activated protein kinases in rat brain following chronic forced swim stress. Behav Brain Res 2006, 175:233-240.
68. Qi X., Lin W., Li J., Li H., Wang W., Wang D., et al. Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol Dis 2008, 31:278-285.
69. Ramiro-Cortés Y., Morán J. Role of oxidative stress and JNK pathway in apoptotic death induced by potassium deprivation and staurosporine in cerebellar granule neurons. Neurochem Int 2009, 55:581-592.
70. Rodrigues A.L., Rocha J.B., Mello C.F., Souza D.O. Effect of perinatal lead exposure on rat behaviour in open-field and two-way avoidance tasks. Pharmacol Toxicol 1996, 79:150-156.
71. Sairanen M., Lucas G., Ernfors P., Castrén M., Castrén E. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. JNeurosci 2005, 25:1089-1094.
72. Shaywitz A.J., Greenberg M.E. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 1999, 68:821-861.
73. Shen H.M., Liu Z.G. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 2006, 40:928-939.
74. Shopsin B. The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study. Acta Neuropsych 2013, 25:113-118.
75. Son H., Banasr M., Choi M., Chae S.Y., Licznerski P., Lee B., et al. Neuritin produces antidepressant actions and blocks the neuronal and behavioral deficits caused by chronic stress. Proc Natl Acad Sci USA 2012, 109:11378-11383.
76. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
77. Stork P.J., Schmitt J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002, 12:258-266.
78. Strnisková M., Barancík M., Ravingerová T. Mitogen-activated protein kinases and their role in regulation of cellular processes. Gen Physiol Biophys 2002, 21:231-255.
79. Tardito D., Perez J., Tiraboschi E., Musazzi L., Racagni G., Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev 2006, 58:115-134.
80. Vázquez de la Torre A., Junyent F., Folch J., Pelegrí C., Vilaplana J., Auladell C., et al. PI3 k/akt inhibition induces apoptosis through p38 activation in neurons. Pharmacol Res 2013, 70:116-125.
81. Ventura J.J., Cogswell P., Flavell R.A., Baldwin A.S., Davis R.J. JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev 2004, 18:2905-2915.
82. Vidal R., Pilar-Cuéllar F., dos Anjos S., Linge R., Treceño B., Vargas V.I., et al. New strategies in the development of antidepressants: towards the modulation of neuroplasticity pathways. Curr Pharm Des 2011, 17:521-533.
83. Vinet J., Carra S., Blom J.M., Brunello N., Barden N., Tascedda F. Chronic treatment with desipramine and fluoxetine modulate BDNF, CaMKKalpha and CaMKKbeta mRNA levels in the hippocampus of transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuropharmacology 2004, 47:1062-1069.
84. Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. JPharmacol Sci 2009, 110:14-28.
85. Wong M.L., Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2001, 2:343-351.
86. World Health Organization The global burden of disease: 2004 update, TableA2: burden of disease in DALYs by cause, sex and income group in WHO regions, estimates for 2004 2008, WHO, Geneva, Switzerland.
87. Yamaguchi T., Nagao S., Wallace D.P., Belibi F.A., Cowley B.D., Pelling J.C., et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 2003, 63:1983-1994.
88. Yeste-Velasco M., Folch J., Casadesús G., Smith M.A., Pallàs M., Camins A. Neuroprotection by c-Jun NH2-terminal kinase inhibitor SP600125 against potassium deprivation-induced apoptosis involves the Akt pathway and inhibition of cell cycle reentry. Neuroscience 2009, 159:1135-1147.
89. Yasuda S., Sugiura H., Tanaka H., Takigami S., Yamagata K. p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases. Cent Nerv Syst Agents Med Chem 2011, 11:45-59.
90. Zhou F., Xu Y., Hou X.Y. MLK3-MKK3/6-P38MAPK cascades following N-methyl-D-aspartate receptor activation contributes to amyloid-β peptide-induced apoptosis in SH-SY5Y cells. JNeurosci Res 2014, 92:808-817.
91. Zomkowski A.D., Hammes L., Lin J., Calixto J.B., Santos A.R., Rodrigues A.L. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 2002, 13:387-391.
92. Zomkowski A.D., Rosa A.O., Lin J., Santos A.R., Calixto J.B., Rodrigues A.L.S. Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res 2004, 1023:253-263.
93. Zomkowski A.D., Santos A.R., Rodrigues A.L. Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci Lett 2005, 381:279-283.